

Lopinavir/ritonavir

S

Third-degree atrioventricular block following off-label use: case report

In a prospective study involving 41 COVID-19 patients, a patient [*age and sex not stated*] was described, who developed third-degree atrioventricular block following off-label treatment with lopinavir/ritonavir for COVID-19.

The patient was admitted in intensive care unit with COVID-19 infection. Therefore, the patient started receiving off-label treatment with lopinavir/ritonavir 200/50mg [*route not stated*] twice a day for 10 days. During the treatment patient developed a third-degree atrioventricular block secondary to lopinavir/ritonavir therapy.

Hence, the patient's lopinavir/ritonavir treatment was discontinued [*duration of treatment to reaction onset and outcome not stated*].

Beyls C, et al. Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia. *Circulation: Arrhythmia and Electrophysiology* 13: e008798, No. 8, Aug 2020. Available from: URL: <http://doi.org/10.1161/CIRCEP.120.008798>

803501888